Last reviewed · How we verify
ALLO-ASC-CD
At a glance
| Generic name | ALLO-ASC-CD |
|---|---|
| Also known as | Allogenic adipose-derived mesenchymal stem cell |
| Sponsor | Anterogen Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial
- A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALLO-ASC-CD CI brief — competitive landscape report
- ALLO-ASC-CD updates RSS · CI watch RSS
- Anterogen Co., Ltd. portfolio CI